DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
about
DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome projectDNA and the chromosome - varied targets for chemotherapyEffect of 5-azacytidine and galectin-1 on growth and differentiation of the human b lymphoma cell line bl36The role of chromatin modifications in somatic embryogenesis in plantsEpigenetic Therapeutics: A New Weapon in the War Against CancerSuccessful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reportsA phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.Measuring topology of low-intensity DNA methylation sites for high-throughput assessment of epigenetic drug-induced effects in cancer cells.Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2'-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis.Aberrant DNA methylation in malignant melanomaDemethylating drugs as novel analgesics for cancer pain.Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cellsDNA methylation topology: potential of a chromatin landmark for epigenetic drug toxicology.Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS methodInhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling.5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.Molecular targets for tumor radiosensitization.Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.Genetic and epigenetic variants in the MTHFR gene are not associated with non-Hodgkin lymphoma.Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease.Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation.AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine.Targeted brain tumor treatment-current perspectivesDNA methylation and cancer diagnosis.Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells.Epigenetic Determinants of Cancer.Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy.Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.
P2860
Q21146392-56B9945E-3654-4C55-8BEA-7C62C37D9D11Q24792540-D9DB25C2-14EA-458D-8BA6-62F51C8C665CQ24805197-971A69A6-879A-4ED4-8D0C-7E4DACB5D830Q26782771-0D36447B-FAA5-475E-8933-65BE0CB54EE0Q28072370-9AF8DA8C-BEE7-4480-9293-15919296EAABQ33407141-4A0F27FB-3EBC-4918-B028-831EFA49DE0CQ33939624-50888D33-21BB-45AF-89DC-D63699315709Q34238573-D9835101-1D58-4251-8E17-F16F629EA9BDQ34450695-9C63C7B0-AA8A-470B-BAF6-08081919D52DQ34516587-F4B7944A-A6D0-49C9-BFBF-9F2BDD309E45Q34959705-3BFD4E3C-8D7C-4D0E-821C-8F711CD10778Q35545116-A6F18B85-735E-4D7E-8984-A2E79F4D2BA3Q35647894-56F2D9FA-BDE6-4011-863B-960329BDC761Q35781849-F9247CF2-F9F4-4F17-BE12-7061B1546781Q35893359-70AB2091-389D-4DFD-B417-694E3BF6A995Q35944714-6BE17C7D-382B-4614-99B3-3B981FF2A076Q36126009-47077947-C92D-4BDF-B6DF-5BE2A967FED1Q36203084-A390F28A-6C4B-4A34-B638-E511F249AD1DQ36251919-BF0A19A6-C7FD-44E1-AFC8-F0F67B0E41BEQ37323162-C52F714D-4D18-4DFE-977A-6DC762448771Q37536495-2ACB564A-7FF9-4AC1-A5F3-1BCFFA0A4739Q37649663-01B8CF51-D637-4BE6-9EA5-4AEBA3E2F9AEQ37928916-DA3F8815-2BE7-4162-A833-50FD4C6B75BDQ38123094-4029CDCA-84DB-40C4-9142-C51DCA87B85DQ38806235-C712C9ED-02C9-4D38-8039-B2624F86388CQ38837858-05F1B62C-D02C-4FD2-87A4-B5788C5CEF27Q41064275-B70A292C-77CC-4F00-BE7E-FA5A6431DA03Q43247519-82440F09-8A96-4660-AA2A-2B5B7FAFE79E
P2860
DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
DNA methylation inhibitors in ...... possible mechanisms of action.
@ast
DNA methylation inhibitors in ...... possible mechanisms of action.
@en
type
label
DNA methylation inhibitors in ...... possible mechanisms of action.
@ast
DNA methylation inhibitors in ...... possible mechanisms of action.
@en
prefLabel
DNA methylation inhibitors in ...... possible mechanisms of action.
@ast
DNA methylation inhibitors in ...... possible mechanisms of action.
@en
P1476
DNA methylation inhibitors in ...... possible mechanisms of action.
@en
P2093
P304
P577
2000-01-01T00:00:00Z